GNH USA

Europe — EMA

Ipstyl Autogel (Lanreotide)

GNH USA supplies Ipstyl Autogel (Lanreotide), a somatostatin analog for acromegaly and neuroendocrine tumors. Request a quote for global supply to you.

Lanreotide

Request sourcing

1
Pack/s

What is Lanreotide?

Lanreotide, the active ingredient in Ipstyl Autogel, is a somatostatin analog presented as a gel (Autogel) for subcutaneous injection use. It is employed to control excess growth hormone production in adults with acromegaly and to manage hormone‑secreting neuroendocrine tumors.

GNH USA supplies Ipstyl Autogel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

What is Lanreotide used for?

Lanreotide is used in the management of hormone‑dependent disorders affecting the growth hormone axis and neuroendocrine secretion.

Acromegaly: reduces serum growth hormone and IGF‑1 levels, helping control disease activity. Neuroendocrine tumors: inhibits hormone secretion and may slow tumor progression. Carcinoid syndrome (functional NETs): alleviates flushing and diarrhea by suppressing vasoactive peptide release.

What are the side effects of Lanreotide?

Common Side Effects: - Injection site pain or erythema - Abdominal discomfort or cramps - Diarrhoea or constipation - Nausea or vomiting - Headache - Mild hyperglycaemia

Serious or Rare Side Effects: - Gallstone formation or biliary colic - Acute pancreatitis - Severe hypersensitivity reactions (anaphylaxis, angioedema) - Significant hyperglycaemia or new‑onset diabetes - Cardiac arrhythmias - Severe hepatic dysfunction

What precautions apply to Lanreotide?

Lanreotide requires careful monitoring in several clinical situations.

Pregnancy: consult a healthcare provider; limited safety data are available. Breastfeeding: avoid unless the benefit outweighs potential risk to the infant. Renal impairment: monitor renal function; dose adjustment may be needed. Diabetes or impaired glucose tolerance: observe blood‑glucose levels as the drug can affect glycaemic control. Gallbladder disease: use with caution due to increased risk of gallstone formation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Lanreotide interact with?

Lanreotide may interact with other medicines that influence hormone levels or cardiac conduction.

Major Interactions (Avoid): - Concurrent use of other somatostatin analogs: additive hormone suppression and heightened gallstone risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lanreotide exposure. - Medications that prolong the QT interval: combined effect may raise the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycaemic agents: lanreotide can alter glucose control, requiring dose adjustments. - Anticholinergic drugs: may exacerbate gastrointestinal side effects such as constipation.

Frequently asked questions

What is Ipstyl Autogel used for?+
Ipstyl Autogel contains lanreotide, a somatostatin analog indicated for the treatment of acromegaly and for controlling hormone secretion in certain neuroendocrine tumors, including carcinoid syndrome. It helps lower excess growth hormone and related peptide levels in adult patients.
How does lanreotide work?+
Lanreotide binds selectively to somatostatin receptors SSTR2 and SSTR5 on endocrine cells. This binding blocks adenylate cyclase, reduces cyclic AMP formation, and suppresses the release of growth hormone, insulin‑like growth factor‑1, and various gastrointestinal hormones, thereby modulating disease‑related hormone excess.
What is the usual dose of Ipstyl Autogel?+
The dosing regimen for Ipstyl Autogel is individualized and determined by the prescribing physician based on the patient’s condition, disease severity, and response to therapy. Healthcare professionals adjust the dose and injection interval according to clinical guidelines and patient monitoring.
Is Ipstyl Autogel safe during pregnancy or breastfeeding?+
Safety data for lanreotide in pregnancy are limited, and the product should only be used if the potential benefit justifies the potential risk to the fetus. During breastfeeding, the drug may be excreted in milk; therefore, it is generally avoided unless the therapeutic advantage outweighs possible risks to the infant.
How do I order Ipstyl Autogel from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.
How does Ipstyl Autogel compare with the main alternative drug?+
The primary alternative to lanreotide is octreotide, another somatostatin analog. Both agents suppress similar hormones, but lanreotide is typically administered as a long‑acting gel every 4–8 weeks, whereas octreotide may require more frequent dosing (monthly depot or daily injections). Choice depends on patient preference, tolerability, and specific clinical considerations.
What are the storage and handling requirements for Ipstyl Autogel?+
Ipstyl Autogel should be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the gel. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.
How is Ipstyl Autogel administered?+
The medication is supplied as a pre‑filled autogel syringe for subcutaneous injection. A healthcare professional injects the gel into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique. The injection site should be rotated to minimize local reactions.
What are the most serious risks associated with Ipstyl Autogel?+
Serious adverse events include gallstone formation, acute pancreatitis, severe hypersensitivity reactions (including anaphylaxis), marked hyperglycaemia or new‑onset diabetes, and cardiac arrhythmias. Patients should be monitored for abdominal pain, jaundice, signs of infection, and any sudden changes in blood glucose or heart rhythm.
Who should not use Ipstyl Autogel?+
Ipstyl Autogel is contraindicated in patients with known hypersensitivity to lanreotide or any excipients in the formulation. Caution is advised for individuals with severe gallbladder disease, uncontrolled diabetes, significant cardiac conduction abnormalities, or those receiving other somatostatin analogs without medical supervision.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lanreotide
Route
Subcutaneous Use
Manufacturer
Institut Produits Synthèse (Ipsen) Ab
Origin
EU

Related products

Ipstyl

Ipstyl

Lanreotide

Ipsen S.P.A.
EU
Ipstyl Autogel

Ipstyl Autogel

Lanreotide

Institut Produits Synthèse (Ipsen) Ab
EU
Lanrenet

Lanrenet

Lanreotide

Mylan S.P.A.
EU
Lanreotid Pharmathen

Lanreotid Pharmathen

Lanreotide

Pharmathen S.A.
EU